This plain language summary published in Future Oncology describes results for the Black participants of the GRIFFIN clinical study, which looked at the treatment combination of daratumumab plus a standard therapy for multiple myeloma (called RVd therapy).
Read the full article here.
The original article on which this plain language summary is based is titled ‘Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN’ and was published in Blood Cancer Journal. Read the original article here.